世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の末梢神経障害治療市場 2018-2022年

Global Peripheral Neuropathy Treatment Market 2018-2022

IRTNTR23934

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年10月US$2,500
シングルユーザライセンス
115

サマリー

この調査レポートは世界の末梢神経障害治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Peripheral Neuropathy
Peripheral neuropathy is a set of symptoms caused by any damage to the nerves that are away from the brain and spinal cord. Peripheral neuropathy is not a single, homogenous disease, but it is a mix of different clinical presentations, natural histories, and pathology.
Technavio’s analysts forecast the Global Peripheral Neuropathy Treatment Market to grow at a CAGR of 3.5% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the peripheral neuropathy treatment market. To calculate the market size, the report considers the revenue generated by the sale of drugs for the treatment of peripheral neuropathy across the globe.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, peripheral neuropathy treatment market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Eli Lilly
- Johnson & Johnson
- Novartis
- Pfizer
- TEVA Pharmaceutical Industries
Market driver
- Growing awareness about peripheral neuropathy
- For a full, detailed list, view our report

Market challenge
- Complications involved in the diagnosis of peripheral neuropathy
- For a full, detailed list, view our report

Market trend
- Development of topical patches for neuropathy treatment
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: PIPELINE LANDSCAPE
PART 08: MARKET SEGMENTATION BY SUBTYPE
- Segmentation by subtype
- Comparison by subtype
- Diabetic peripheral neuropathy - Market size and forecast 2017-2022
- Chemotherapy-induced peripheral neuropathy - Market size and forecast 2017-2022
- Others - Market size and forecast 2017-2022
- Market opportunity by subtype
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Eli Lilly
- Johnson & Johnson
- Novartis
- Pfizer
- TEVA Pharmaceutical Industries
PART 16: APPENDIX
- List of abbreviations


-
-
Exhibit 01: Parent market
Exhibit 02: Global neuropathy pain treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global peripheral neuropathy treatment market - Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global peripheral neuropathy treatment market - Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase 2017-2018
Exhibit 19: Key clinical trials 2017-2018
Exhibit 20: Global peripheral neuropathy treatment market by subtype - Market share 2017-2022 (%)
Exhibit 21: Comparison by subtype
Exhibit 22: Diabetic peripheral neuropathy - Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Diabetic peripheral neuropathy - Year-over-year growth 2018-2022 (%)
Exhibit 24: Chemotherapy-induced peripheral neuropathy - Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Chemotherapy-induced peripheral neuropathy - Year-over-year growth 2018-2022 (%)
Exhibit 26: Others - Market size and forecast 2017-2022 ($ mn)
Exhibit 27: Others - Year-over-year growth 2018-2022 (%)
Exhibit 28: Market opportunity by subtype
Exhibit 29: Customer landscape
Exhibit 30: Global peripheral neuropathy treatment market by geography - Market share 2017-2022 (%)
Exhibit 31: Regional comparison
Exhibit 32: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 33: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 34: Top 3 countries in Americas
Exhibit 35: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 36: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in EMEA
Exhibit 38: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 39: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in APAC
Exhibit 41: Market opportunity
Exhibit 42: Companies contributing to the development of late-stage therapeutics for peripheral neuropathy
Exhibit 43: Recent drug approvals for the treatment of peripheral neuropathy
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Eli Lilly: Overview
Exhibit 50: Eli Lilly - Business segments
Exhibit 51: Eli Lilly - Organizational developments
Exhibit 52: Eli Lilly - Geographic focus
Exhibit 53: Eli Lilly - Segment focus
Exhibit 54: Eli Lilly - Key offerings
Exhibit 55: Eli Lilly - Key customers
Exhibit 56: Johnson & Johnson: Overview
Exhibit 57: Johnson & Johnson Services - Business segments
Exhibit 58: Johnson & Johnson - Organizational developments
Exhibit 59: Johnson & Johnson - Geographic focus
Exhibit 60: Johnson & Johnson - Segment focus
Exhibit 61: Johnson & Johnson - Key offerings
Exhibit 62: Johnson & Johnson - Key customers
Exhibit 63: Novartis: Overview
Exhibit 64: Novartis - Business segments
Exhibit 65: Novartis - Organizational developments
Exhibit 66: Novartis - Geographic focus
Exhibit 67: Novartis - Segment focus
Exhibit 68: Novartis - Key offerings
Exhibit 69: Novartis - Key customers
Exhibit 70: Pfizer: Overview
Exhibit 71: Pfizer - Business segments
Exhibit 72: Pfizer - Organizational developments
Exhibit 73: Pfizer - Geographic focus
Exhibit 74: Pfizer - Segment focus
Exhibit 75: Pfizer - Key offerings
Exhibit 76: Pfizer - Key customers
Exhibit 77: TEVA Pharmaceutical Industries: Overview
Exhibit 78: TEVA Pharmaceutical Industries - Business segments
Exhibit 79: TEVA Pharmaceutical Industries - Organizational developments
Exhibit 80: TEVA Pharmaceutical Industries - Geographic focus
Exhibit 81: TEVA Pharmaceutical Industries - Segment focus
Exhibit 82: TEVA Pharmaceutical Industries - Key offerings
Exhibit 83: TEVA Pharmaceutical Industries - Key customers




 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る